29 Jul Exact Sciences to buy California-based Genomic Health for $2.8 billion
Madison-based cancer diagnostics company Exact Sciences Corp. said Monday it plans to acquire Redwood City, California-based Genomic Health in a $2.8 billion cash-and-stock deal.
Exact Sciences produces Cologuard, a noninvasive, at-home screening test that detects the presence of colon cancer in stool samples.
Genomic Health develops Oncotype IQ, a portfolio of genomic tests and services that check for various cancers, including breast and prostate.
Sorry, the comment form is closed at this time.